Ardelyx (ARDX) vs Kura Oncology (KURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Kura Oncology (KURA) has outperformed Ardelyx (ARDX) over the past year, losing 7.7% versus a loss of 38.8%. Over five years, ARDX leads with a +171.1% price change compared with -48.3% for KURA. Kura Oncology is the larger company by market cap ($807.8 million vs $797.8 million), about 1.0 times the size.
Ardelyx converts more of its revenue into profit, with a net margin of -15.1% versus -412.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | KURA |
|---|---|---|
| Share price | $3.09 | $9.08 |
| Market cap | $797.80M | $807.76M |
| 1-day change | -5.50% | -6.39% |
| YTD return | -47.00% | -12.61% |
| 1-year return | -38.81% | -7.72% |
| 5-year return | +171.05% | -48.29% |
| Forward P/E | 10.64 | — |
| EPS (TTM) | $-0.23 | $-3.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $407.32M | $67.48M |
| Revenue growth (YoY) | +22.09% | +25.24% |
| Net income (latest FY) | $-61.60M | $-278.67M |
| Gross margin | 90.29% | — |
| Operating margin | -10.06% | -449.94% |
| Net margin | -15.12% | -412.95% |
| 52-week high | $8.40 | $13.90 |
| 52-week low | $3.06 | $7.36 |
| Distance from 52-week high | -63.21% | -34.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +317.48% | +250.77% |
| Average volume | 4.36M | 1.82M |
| Shares outstanding | 258.19M | 88.96M |
| Employees | 489 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KURA has outperformed ARDX by 31.1 percentage points over the past year.
- Ardelyx is more profitable, keeping -15.1 cents of every revenue dollar as net income versus -412.9 cents for Kura Oncology.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Kura Oncology
KURA stock →Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
ARDX vs KURA FAQ
Which is bigger, Ardelyx or Kura Oncology?
Kura Oncology (KURA) is larger, with a market capitalization of $807.76M compared with $797.80M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or KURA?
KURA returned -7.72% over the past 12 months, compared with -38.81% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Kura Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.